Envelope surface glycoprotein gp120
|
env
|
HIV-1 IIIB Env (gp120) upregulates production of TNF (TNF-a), IL-17A, CCL2 (MCP1), CCL5 (RANTES), IL6, IL10, CXCL8 (IL8), CXCL1 (GRO-a), and CCL1 (I309) in stimulated monocyte derived macrophages |
PubMed
|
|
env
|
HIV-1 CN54, JRFL, and Ada Env (gp120) upregulates IL-6, CCL2, CCL4, CXCL8, and IL-1b through TLR4 and CCR5 induction in monocyte derived macrophages and hepatic stellate cells because treatment with an anti-TLR4 antibody mitigated the response |
PubMed
|
|
env
|
HIV-1 JRFL (gp120) upregulates CCL2 in ARPE-19 cells |
PubMed
|
|
env
|
HIV-1 gp120-induced release of IL-6 and MCP-1 is partially responsible for the impairment of barrier function in human retinal pigment epithelial cells |
PubMed
|
|
env
|
CXCR4-tropic HIV-1 gp120 augments the expression of RANTES, IP-10, MCP-1, and LTN in peripheral blood mononuclear cells (PBMCs), while CCR5-tropic HIV-1 gp120 also induces an increase in both IP-10 and MCP-1 production |
PubMed
|
|
env
|
Upregulation of the human proteins CCL2, CX3CL1, IL-1beta, and CXCL10 by HIV-1 gp120 involves CB2 receptor in mesencephalic neuronal/glial culture model |
PubMed
|
|
env
|
HIV-1 gp120 upregulates the expression of chemokine (C-C motif) ligand 2 (CCL2) in human B cells |
PubMed
|
|
env
|
Nuclear PI-PLC beta 1 plays as a new intermediate in the gp120-triggered PC-PLC-driven signal transduction pathway leading to CCL2 secretion in macrophages |
PubMed
|
|
env
|
The interaction of HIV-1 gp120 with CCR5 triggers PC-PLC activation and CCL2 secretion in human monocyte-derived macrophages |
PubMed
|
|
env
|
Phosphatidylcholine-specific phospholipase C (PC-PLC) signaling pathway modulates HIV-1 gp120-induced CCL2 production in human monocyte-derived macrophages |
PubMed
|
|
env
|
CCL2 upregulates CXCR4 on resting CD4(+) T cells in a CCR2-dependent mechanism, increases the ability of these cells to be chemoattracted to CXCR4 using gp120 and renders them more permissive to X4-tropic HIV-1 infection |
PubMed
|
|
env
|
Treatment of macrophages (MDM) with recombinant gp120-IIIB results in a specific and dose-dependent enhancement of secretion of monocyte chemoattractant protein-1, macrophage inflammatory protein-1beta, and RANTES |
PubMed
|
|
env
|
Treatment of human hepatic stellate cells with gp120 significantly increases secretion and gene expression of CCL2, metalloprotease-1 and interleukin-6. Gp120 also induces activation of Akt, NF-kappaB, and p38(MAPK) |
PubMed
|
Envelope transmembrane glycoprotein gp41
|
env
|
The HIV-1 gp41 transmembrane domain inhibits TLR2-induced activation of ERK1/2, and secretion of TNF-alpha, MCP-1, and IL-6 |
PubMed
|
|
env
|
A synthetic peptide corresponding to the immunosuppressive domain (amino acids 574-592) of HIV-1 gp41 inhibits activation of PBMCs and upregulates the expression of MCP-1 in peptide-treated PBMCs |
PubMed
|
Nef
|
nef
|
Jurkat cells infected with HIV-1 induces a stronger endothelial MCP-1 release and apoptosis in comparison to Nef-deleted HIV-1, suggesting that Nef is responsible for HIV-induced endothelial cell death and activation |
PubMed
|
|
nef
|
HIV-1 Nef inhibits CCL-2 induced chemotaxis in Jurkat cells, monocytes, and PBMCs, which leads to marked downregulation of F-actin accumulation in cells |
PubMed
|
|
nef
|
HIV-1 Nef upregulates CCL-2/MCP-1 expression in astrocytes and this upregulation by Nef depends on the myristoylation moiety (residues 2-3) of Nef and requires functional calmodulin |
PubMed
|
Pr55(Gag)
|
gag
|
Neutralization of endogenous CCL2 by Abs induces cellular A3A expression, inhibits HIV-1 Gag+ MDM cells, and impairs HIV-1 DNA accumulation in MDM |
PubMed
|
|
gag
|
MVA-gag induces a significant release of cytokines such as IL-2R, IL-6, IL-8, TNF-alpha, IFN-gamma, MCP-1, MIP-1alpha, MIP-1beta, and RANTES by the infected monocyte-derived dendritic cells in comparison with uninfected cells |
PubMed
|
Tat
|
tat
|
HIV-1 Tat upregulates CCL2 mRNA and protein expression in CRT-MG human astroglioma cells |
PubMed
|
|
tat
|
HIV-1 Tat upregulates MCP-1 expression, an effect that may contribute to the pathogenesis of Tat associated with AIDS dementia |
PubMed
|
|
tat
|
HIV-1 Tat inhibitor didehydro-Cortistatin A (dCA), an analog of a natural steroidal alkaloid, potently inhibits Tat-mediated modulation of IL-1beta, TNF-alpha and MCP-1 |
PubMed
|
|
tat
|
HIV-1 Tat-induced release of CCL2 from human astrocytes is regulated by P2RX7 |
PubMed
|
|
tat
|
Upregulation of MCP-1 by HIV-1 Tat in astrocytes is inhibited by the MEK1/2 inhibitor UO126, indicating a role for MEK1/2 in Tat-mediated chemokine induction |
PubMed
|
|
tat
|
Microarray analysis indicates HIV-1 Tat-induced upregulation of chemokine (C-C motif) ligand 2 (CCL2; MCP-1) in primary human brain microvascular endothelial cells |
PubMed
|
|
tat
|
LRRK2 is involved in HIV-1 Tat-induced cytokine TNF-alpha, IL-6, and MCP-1 expression in microglia cells |
PubMed
|
|
tat
|
The endogenous PPARgamma ligand 15d-PGJ2 inhibits HIV-1 Tat-induced MCP-1 production in human microglia-like cells |
PubMed
|
|
tat
|
HIV-1 Tat downregulates the expression of adiponectin protein and upregulates the expression of IL-6, IL-8, and MCP-1 proteins in human SGBS preadipocytes |
PubMed
|
|
tat
|
Over-expression of PPARalpha or PPARgamma attenuates Tat-induced up-regulation of inflammatory mediators, such as interleukin (IL)-1beta, tumor necrosis factor-alpha, CCL2, and E-selectin |
PubMed
|
|
tat
|
CDK9 is involved in Tat-induced MCP-1/CCL2 gene expression in human astrocytes |
PubMed
|
|
tat
|
Astrocyte cultures treated with morphine and Tat show exaggerated increases in chemokine release, including monocyte chemoattractant protein-1 (MCP-1), RANTES, and IL-6 |
PubMed
|
|
tat
|
Upregulation of MCP-1 by HIV-1 Tat is mediated at the transcriptional level and is regulated, at least in part, by NF-kappa B, AP1, Sp1, protein kinase C and PI3 kinase |
PubMed
|
|
tat
|
HIV-1 Tat is a competitive inhibitor of MCP-1 binding to CCR2 |
PubMed
|
|
tat
|
MCP-1 and RANTES have been shown to inhibit Tat-induced apoptosis of mixed cultures of human neurons and astrocytes |
PubMed
|
|
tat
|
The C-terminal MH2 domain of Smad3 can decrease the levels of HIV-1 Tat-induced activation of MCP-1 in astrocytic cells |
PubMed
|
|
tat
|
Tat-mediated upregulation of MCP-1 transcription is stimulated by Smad-3 and decreased by Smad-4 |
PubMed
|
Vpr
|
vpr
|
Treatment of human primary astrocytes with HIV-1 Vpr upregulates secretion of IL-6, IL-8, MCP-1, and MIF and downregulates secretion of serpin E1, a serine proteinase inhibitor (known as PAI-1) |
PubMed
|
matrix
|
gag
|
Treatment of human PBMCs with HIV-1 MA upregulates the expression of MCP-1, ICAM-1, CD40, CD86 and CD36 and downregulates the expression of nuclear receptors FXR and PPARgamma |
PubMed
|
|
gag
|
HIV-1 matrix activates monocytes to produce MCP-1, which depends on the binding activity of AP-1 complexes (c-Fos/JunB) in the MCP-1 promoter |
PubMed
|